The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and ...

Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, ...

A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...

A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared ...

The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands ...

Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic ...

The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a ...

Number 5: Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...